HFE and Non-HFE Hemochromatosis

Progress in hematology

Abstract

Hereditary hemochromatosis (HH) is a disorder of iron metabolism in which enhanced absorption of dietary iron causes increased iron accumulation in the liver, heart, and pancreas. Most individuals with HH are homozygous for a point mutation in theHFE gene, leading to a C282Y substitution in the HFE protein. The function of HFE protein is unknown, but the available evidence suggests that it acts in association with β2-microglobulin and transferrin receptor 1 to regulate iron uptake from plasma transferrin by the duodenum, the proposed mechanism by which body iron levels are sensed. The identification of HFE has established the foundation for a better understanding of the molecular and cellular biology of iron homeostasis and its altered regulation in HH. Additionally, the ability to accurately diagnose iron overload disorders has been strengthened, family screening has been improved, and evaluation of patients with other forms of liver disease complicated by moderate-to-severe iron overload is now possible. However, the role of HFE testing in generalized population screening for HH is still controversial. Recently, other forms of HH have been described that are not related to HFE but are due to mutations in genes coding iron transport proteins.

Key words

Iron Iron overload Hemochromatosis Thalassemia HFE IREG1 TfR2 

References

  1. 1.
    Anderson GJ. Ironing out disease: inherited disorders of iron homeostasis.IUBMB Life. 2001;51:11–17.PubMedGoogle Scholar
  2. 2.
    Bacon BR, Powell LW, Adams PC, et al. Molecular medicine and hemochromatosis: at the crossroads.Gastroenterology. 1999;116: 193–207.PubMedCrossRefGoogle Scholar
  3. 3.
    Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis.Nat Genet. 1996;13:399–408.PubMedCrossRefGoogle Scholar
  4. 4.
    Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.Gastroenterology. 1998;11:929–936.CrossRefGoogle Scholar
  5. 5.
    George DK, Ramm GA,Walker NI, et al. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in hemochromatosis.J Hepatol. 1999;31:47–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Cullen LM, Anderson GJ, Ramm GA, Jazwinska EC, Powell LW. Genetics of hemochromatosis.Annu Rev Med. 1999;50:87–98.PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson GJ,Vulpe CD. Regulation of intestinal iron transport. In: Templeton DM, ed.Molecular and Cellular Iron Transport. New York: Marcel Dekker; 2002:559–596.Google Scholar
  8. 8.
    Trinder D, Olynyk JK, Sly WS, Morgan EH. Iron uptake from plasma transferrin by the duodenum is impaired in the HFE knock-out mouse.Proc Natl Acad Sci. 2002;99:5622–5626.PubMedCrossRefGoogle Scholar
  9. 9.
    Tavill AS. Management of hemochromatosis. (AASLD Practice Guidelines)Hepatology. 2001;33:1321–1328.PubMedCrossRefGoogle Scholar
  10. 10.
    EASL International Consensus Conference on Hemochromatosis.J Hepatol. 2000;33:485–504.CrossRefGoogle Scholar
  11. 11.
    Camaschella C, Roetto A, De Gobbi M, et al. Non-HFE hemochromatosis. In: Proceedings from the World Congress on Iron Metabolism. August 18-23, 2001. Cairns, Australia.Google Scholar
  12. 12.
    Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of hemochromatosis mapping to 7q22.Nat Genet. 2000;25:14–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene.N Engl J Med. 1999;341:725–732.PubMedCrossRefGoogle Scholar
  14. 14.
    Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.J Clin Invest. 2001;108:619–623.PubMedGoogle Scholar
  15. 15.
    Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.Nat Genet. 2001;28:213–214.PubMedCrossRefGoogle Scholar
  16. 16.
    Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin 1 is associated with autosomal dominant hemochromatosis.Blood. 2002;100:692–694.PubMedCrossRefGoogle Scholar
  17. 17.
    Kato J, Fujikawa K, Kanda M, et al.A mutation, in the iron responsive element of H ferritin mRNA, causing autosomal dominant iron overload.Am J Hum Genet. 2001;69:191–197.PubMedCrossRefGoogle Scholar
  18. 18.
    Eason RJ, Adams PC, Aston CE, Searle J. Familial iron overload with possible autosomal dominant inheritance.Aust NZ J Med. 1990;20:226–230.Google Scholar
  19. 19.
    Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the hemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda.Lancet. 1997;349:321–323.PubMedCrossRefGoogle Scholar
  20. 20.
    Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in hemochromatosis (HFE) gene and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients.J Hepatol. 1998;28:404–409.PubMedCrossRefGoogle Scholar
  21. 21.
    Sampietro M, Piperno A, Lupica L, et al. High prevalence of His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.Hepatology. 1998;27:181–184.PubMedCrossRefGoogle Scholar
  22. 22.
    Sullivan JL. Iron and the genetics of cardiovascular disease [editorial; comment].Circulation. 1999;100:1260–1263.PubMedGoogle Scholar
  23. 23.
    Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major.N Engl J Med. 2000;343:327–331.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  1. 1.Iron Metabolism LaboratoryThe Queensland Institute of Medical Research and The University of QueenslandBrisbaneAustralia

Personalised recommendations